Skip to main content

ORAGENICS INC

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

OGEN$0.34-3.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

For the Six Months Ended June 30,
20262025
Cash flows from operating activities:
Net loss$(4,729,950)$(4,489,028)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and closing costs-771,437
Stock-based compensation expense34,96924,485
Stock-based compensation recapture expense-(86,617)
Common stock issued for services5,000-
Changes in operating assets and liabilities:
Interest receivable53,082-
Prepaid expenses and other current assets(13,361)441,707
Accounts payable and accrued expenses262,856(88,444)
Net cash used in operating activities(4,387,404)(3,426,460)
Cash flows from investing activities:
Proceeds from sale of short-term investments4,000,000-
Net cash provided by investing activities4,000,000-
Cash flows from financing activities:
Borrowings on short-term notes payable-2,228,563
Payments on short-term notes payable(227,348)(328,528)
Net proceeds from issuance of common stock79,2102,635,330
Net cash (used) provided by financing activities(148,138)4,535,365
Net changes in cash and cash equivalents(535,542)1,108,905
Cash and cash equivalents at beginning of period4,399,726864,840
Cash and cash equivalents at end of period$3,864,184$1,973,745
Supplemental disclosure of cash flow information:
Interest paid$4,141$7,860
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.